Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis

Table 3

Discriminative performance of individual clinical parameters and biomarker candidates for BCa recurrence.

Clinical parameter	Pr (>)	AUC	Biomarker candidate	Pr (>)	AUC
diagnosis2sample	0.42	0.50		0.67	0.57
gender	0.89	0.51		0.05	0.67
age.diagnosis	0.70	0.48		0.08	0.69
age.sample	0.45	0.57		0.66	0.53
grade.diagnosis (G2/G3)	0.32/0.48	0.57		0.65	0.48
stage.diagnosis	0.52	0.55		0.09	0.65
no.past.recurrences	0.08	0.63		0.86	0.53
BCG.therapy	0.10	0.65		0.06	0.73
mitomycin.therapy	0.49	0.54		0.90	0.50
no.past.TURBTs	0.33	0.58		0.72	0.58
				0.74	0.47
				0.46	0.50
				0.54	0.52

Clinical parameters and biomarker candidates with the best individual AUC.
(a) grade.diagnosis: tumor grade at time of diagnosis; stage.diagnosis: tumor stage at time of diagnosis. The other clinical parameters are defined in the Specimen and Data Collection.
(b) G2/G3: grade 2/grade 3.
(c) Biomarkers ending with chip were measured with the BCa chip and markers ending with AP were measured with the automated platform for 96-well plate ELISA analysis.